Abstracts

Filters

Clear Filters
All Days Sun, Sep 28 Mon, Sep 29 Tue, Sep 30 Wed, Oct 01

Sunday, September 28

3:00 PM - 3:10 PM PT

124 - Tracking Changes in B Cell Antibodies in Cervical Cancer Patients Treated with Chemoradiation and Immunotherapy on GOG 9929
Speaker: Kim, Sangwoo, MD - University of California, San Diego, La Jolla, CA
3:00 PM - 3:10 PM PT

130 - High-Dimensional Immunophenotyping of Patients with Localized Non-Small Cell Lung Cancer (NSCLC) Reveals Distinct Immune Cell Subsets Predictive of Disease-Free Survival (DFS) in AFT-16 and LCMC3 Phase II Immunotherapy Clinical Trials
Speaker: Eustace, Nicholas, MD, PhD - City of Hope National Medical Center, Duarte, CA
3:00 PM - 3:10 PM PT

137 - Exploiting Dependencies Created By KEAP1/NFE2L2 Mutations in NSCLC to Overcome Radiation Resistance
Speaker: Mai, Wilson, MD, PhD - Stanford University Cancer Center, Stanford, CA
3:10 PM - 3:20 PM PT

104 - Deep Learning-Based Personalized Blood Dosimetry (OncoBlood) for Circulating Blood Cell Exposure Predicts Radiation-Induced Severe Lymphopenia and Survival Outcomes in Craniospinal Irradiation
Speaker: Seo, Sang Hoon, MD - Oncosoft, Seoul, SEO
3:10 PM - 3:20 PM PT

111 - Perioperative Chemotherapy Duration Affects the Survival of Locally Advanced Rectal Cancer: A Post-Hoc Analysis of a Multicenter Randomized, Phase III Trial
Speaker: Xu, Tongzhen, MD - Chinese Academy of Medical Science, Bejing, Beijing
3:10 PM - 3:20 PM PT

118 - Phase III Study of Hypofractionated, Dose Escalation Radiotherapy vs. Conventional Pelvic Radiation Therapy followed by High Dose Rate Brachytherapy Boost for High Risk Adenocarcinoma of the Prostate (PCS VI)
Speaker: Niazi, Tamim, MD - McGill University, Montreal, QC
3:10 PM - 3:20 PM PT

125 - Hypofractionated Radiotherapy as a Potential Alternative to Conventional Treatment for Cervical Cancer in Resource-Limited Setting: A Prospective Comparative Analysis
Speaker: Mallum, Abba, MD, PhD - Department of Radiotherapy and Oncology, Inkosi Albert Luthuli Central Hospital, Durban
3:10 PM - 3:20 PM PT

131 - Gut Microbiota Predictive of Consolidation Immunotherapy Efficacy and Toxicity after Chemoradiotherapy in Lung Cancer
Speaker: Li, Yitong, MD - National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy, Beijing, Beijing
3:10 PM - 3:20 PM PT

138 - Radiation-Enhanced CD24 Membrane Trafficking via GPI Anchoring Underlies Immune Evasion after Radiotherapy
Speaker: Kong, Lingyi, MD - Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei
3:20 PM - 3:30 PM PT

105 - Use of Gadolinium Nanoparticles as Radiosensitizers for Brain Metastases: Results from the Phase 2 Multicentric Randomized Trial (NANORAD2)
Speaker: Verry, Camille, MD - Centre Hospitalier Universitaire Grenoble Alpes, Grenoble
3:20 PM - 3:30 PM PT

112 - Efficacy and Safety of Short-Course Radiotherapy Followed By Sequential Chemotherapy and AK104 in Locally Advanced Rectal Cancer: Results from a Prospective, Multicenter Phase II Trial
Speaker: Xu, Tongzhen, MD - Chinese Academy of Medical Science, Bejing, Beijing
3:20 PM - 3:30 PM PT

119 - Conventional vs. Hypofractionated, Radiotherapy for High-Risk Prostate Cancer: 10-Year Outcomes of the Randomized, Non-Inferiority, Phase 3 PCS5 Trial
Speaker: Niazi, Tamim, MD - McGill University, Montreal, QC